FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892906275> ?p ?o ?g. }

• W2892906275 endingPage "648" @default.
• W2892906275 startingPage "636" @default.
• W2892906275 abstract "Recently, compound KA-11 was identified as a promising candidate for a new broad-spectrum anticonvulsant. This compound revealed wide protective activity across the most important animal models of seizures such as the maximal electroshock test (MES), the subcutaneous pentylenetetrazole test ( scPTZ), and the six-hertz test (6 Hz, 32 mA). Importantly, KA-11 was devoid of acute neurological activity, which was assessed by applying the chimney test (TD50 value higher than 1500 mg/kg). The preliminary in vivo results confirmed favorable anticonvulsant and safety properties of KA-11. With the aim of further biological characterization of KA-11, in the current studies we evaluated its antiepileptogenic activity in the kindling model of epilepsy induced by repeated injection of PTZ in mice. Furthermore, we assessed the antinociceptive activity of KA-11 in several animal pain models. As a result, KA-11 (at all doses applied: 25, 50, and 100 mg/kg) significantly delayed the progression of kindling induced by repeated injection of PTZ in mice. Additionally, KA-11 revealed potent antinociceptive activity in the formalin-induced tonic pain and, importantly, in the oxaliplatin-induced neuropathic pain model in mice. Moreover, KA-11 did not induce motor deficits in the rotarod test. Patch-clamp experiments revealed that one of the mechanisms of action of KA-11 is inhibition of voltage-gated sodium currents. Compound KA-11 appeared to be safe in relation to hepatotoxic properties as no phospholipidosis induction was determined in HepG2 cells at 50 μM, and a small, statistically significant decrease of cell viability was observed only at the highest used dose of 100 μM. Moreover, KA-11 did not affect the function of CYP2D6. The aforementioned hybrid substance proved to penetrate the biological membranes in the in vitro permeability assays." @default.
• W2892906275 created "2018-10-05" @default.
• W2892906275 creator A5008486745 @default.
• W2892906275 creator A5019754051 @default.
• W2892906275 creator A5031618235 @default.
• W2892906275 creator A5036187783 @default.
• W2892906275 creator A5041415177 @default.
• W2892906275 creator A5047884679 @default.
• W2892906275 creator A5060071703 @default.
• W2892906275 creator A5073818963 @default.
• W2892906275 creator A5074661187 @default.
• W2892906275 creator A5077746708 @default.
• W2892906275 creator A5081072732 @default.
• W2892906275 date "2018-09-24" @default.
• W2892906275 modified "2023-10-18" @default.
• W2892906275 title "KA-11, a Novel Pyrrolidine-2,5-dione Derived Broad-Spectrum Anticonvulsant: Its Antiepileptogenic, Antinociceptive Properties and in Vitro Characterization" @default.
• W2892906275 cites W1492552461 @default.
• W2892906275 cites W1602445767 @default.
• W2892906275 cites W1902073326 @default.
• W2892906275 cites W1971840456 @default.
• W2892906275 cites W1973301280 @default.
• W2892906275 cites W1981607546 @default.
• W2892906275 cites W1984264616 @default.
• W2892906275 cites W1987398739 @default.
• W2892906275 cites W1992941083 @default.
• W2892906275 cites W2000341627 @default.
• W2892906275 cites W2001925573 @default.
• W2892906275 cites W2010813263 @default.
• W2892906275 cites W2015811644 @default.
• W2892906275 cites W2019178697 @default.
• W2892906275 cites W2025690146 @default.
• W2892906275 cites W2036712476 @default.
• W2892906275 cites W2041317342 @default.
• W2892906275 cites W2042648593 @default.
• W2892906275 cites W2045131333 @default.
• W2892906275 cites W2049856931 @default.
• W2892906275 cites W2051573709 @default.
• W2892906275 cites W2056741090 @default.
• W2892906275 cites W2060344358 @default.
• W2892906275 cites W2060448500 @default.
• W2892906275 cites W2060534207 @default.
• W2892906275 cites W2061247854 @default.
• W2892906275 cites W2071797336 @default.
• W2892906275 cites W2074563786 @default.
• W2892906275 cites W2076710266 @default.
• W2892906275 cites W2098746681 @default.
• W2892906275 cites W2104474697 @default.
• W2892906275 cites W2105268216 @default.
• W2892906275 cites W2106851317 @default.
• W2892906275 cites W2165232112 @default.
• W2892906275 cites W2175773713 @default.
• W2892906275 cites W2214669686 @default.
• W2892906275 cites W2252355909 @default.
• W2892906275 cites W2295553758 @default.
• W2892906275 cites W2346585656 @default.
• W2892906275 cites W2425862959 @default.
• W2892906275 cites W2539259494 @default.
• W2892906275 cites W2610929100 @default.
• W2892906275 cites W2736312583 @default.
• W2892906275 cites W2738908625 @default.
• W2892906275 cites W2753063582 @default.
• W2892906275 cites W2756787487 @default.
• W2892906275 cites W2789692188 @default.
• W2892906275 cites W2797420849 @default.
• W2892906275 cites W2809362554 @default.
• W2892906275 cites W3023303859 @default.
• W2892906275 doi "https://doi.org/10.1021/acschemneuro.8b00476" @default.
• W2892906275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30247871" @default.
• W2892906275 hasPublicationYear "2018" @default.
• W2892906275 type Work @default.
• W2892906275 sameAs 2892906275 @default.
• W2892906275 citedByCount "31" @default.
• W2892906275 countsByYear W28929062752019 @default.
• W2892906275 countsByYear W28929062752020 @default.
• W2892906275 countsByYear W28929062752021 @default.
• W2892906275 countsByYear W28929062752022 @default.
• W2892906275 countsByYear W28929062752023 @default.
• W2892906275 crossrefType "journal-article" @default.
• W2892906275 hasAuthorship W2892906275A5008486745 @default.
• W2892906275 hasAuthorship W2892906275A5019754051 @default.
• W2892906275 hasAuthorship W2892906275A5031618235 @default.
• W2892906275 hasAuthorship W2892906275A5036187783 @default.
• W2892906275 hasAuthorship W2892906275A5041415177 @default.
• W2892906275 hasAuthorship W2892906275A5047884679 @default.
• W2892906275 hasAuthorship W2892906275A5060071703 @default.
• W2892906275 hasAuthorship W2892906275A5073818963 @default.
• W2892906275 hasAuthorship W2892906275A5074661187 @default.
• W2892906275 hasAuthorship W2892906275A5077746708 @default.
• W2892906275 hasAuthorship W2892906275A5081072732 @default.
• W2892906275 hasConcept C118552586 @default.
• W2892906275 hasConcept C150903083 @default.
• W2892906275 hasConcept C15490471 @default.
• W2892906275 hasConcept C170493617 @default.
• W2892906275 hasConcept C185592680 @default.
• W2892906275 hasConcept C207001950 @default.
• W2892906275 hasConcept C2775858608 @default.
• W2892906275 hasConcept C2776175493 @default.
• W2892906275 hasConcept C2777107010 @default.

• next